Likelihood of Approval and Phase Transition Success Rate Model – (Estradiol + Norethindrone Acetate + Relugolix) in Endometriosis
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – (Estradiol + Norethindrone Acetate + Relugolix) in Endometriosis report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


(Estradiol + Norethindrone Acetate + Relugolix) in Endometriosis Drug Details:
Estradiol, Norethindrone acetate and Relugolix (Myfembree, Ryeqo) is a fixed dose combination product. It is formulated as film coated tablets and tablets for oral route of administration. It is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. It is also indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, management of moderate to severe pain associated with endometriosis.A fixed-dose combination of estradiol, norethindrone acetate and relugolix is under development for the treatment of heavy menstrual bleeding and pain associated with uterine fibroids, pain associated with endometriosis and female contraception. It is administered through oral route as tablet. Relugolix acts by targeting gonadotropin-releasing hormone receptor (GNRHR), estradiol acts by targeting estrogen receptor and norethindrone acetate acts by targeting progesterone receptor.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – (Estradiol + Norethindrone Acetate + Relugolix) LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports